Shilanski & Associates
TEVA icon

Shilanski & Associates’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Shilanski & Associates’s Portfolio TEVA Stock Details TEVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-10,115
Closed -$170K – 132
2025
Q2 		$170K Sell
10,115
-133
-1% -$2.15K 0.05% 108
2025
Q1 		$158K Buy
10,248
+459
+5% +$8.2K 0.05% 104
2024
Q4 		$216K Buy
+9,789
New +$178K 0.07% 98

Other funds holding TEVA

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
Phoenix Financial
Phoenix Financial Givatayim, Israel $14.8B AUM 42.86% 1-Year Est. Return
Menora Mivtachim Holdings
Menora Mivtachim Holdings Ramat Gan, Israel $25.6B AUM 50.04% 1-Year Est. Return
Harel Insurance Investments & Financial Services
Harel Insurance Investments & Financial Services Ramat Gan, Israel $21.3B AUM 44.31% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $1T AUM
Migdal Insurance & Financial Holdings
Migdal Insurance & Financial Holdings Petach Tikva, Israel $16.3B AUM 54.64% 1-Year Est. Return
Clal Insurance
Clal Insurance Tel-Aviv, Israel $20.7B AUM 58.31% 1-Year Est. Return
Lingotto Investment Management
Lingotto Investment Management London, United Kingdom $5.74B AUM 42.24% 1-Year Est. Return
Rubric Capital Management (New York)
Rubric Capital Management (New York) New York $10.9B AUM 70.31% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return

Shilanski & Associates's TEVA Position: Q3 2025 in Review

Shilanski & Associates sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q3 2025, closing a stake of 10,115 shares — an estimated $170K sold.

Shilanski & Associates first reported a position in TEVA in Q4 2024 and held it in 3 quarters. The position peaked at $216K in Q4 2024. 557 funds tracked by Wall St. Rank hold TEVA as of Q3 2025.

  • Shilanski & Associates reported no remaining Teva Pharmaceutical Industries Limited position as of Q3 2025 after selling out during the quarter.
  • Shilanski & Associates sold 10,115 Teva Pharmaceutical Industries Limited shares in Q3 2025, an estimated $170K.
  • Shilanski & Associates first reported a position in Teva Pharmaceutical Industries Limited in Q4 2024 and held it in 3 quarters.
  • Shilanski & Associates's Teva Pharmaceutical Industries Limited position peaked at $216K in Q4 2024.
  • 557 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q3 2025.

Based on Shilanski & Associates's 13F filing for Q3 2025, filed 20 Oct 2025.